ABN Amro Investment Solutions Has $49.33 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

ABN Amro Investment Solutions decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 125,960 shares of the pharmaceutical company’s stock after selling 4,331 shares during the period. Vertex Pharmaceuticals comprises 1.0% of ABN Amro Investment Solutions’ portfolio, making the stock its 28th biggest position. ABN Amro Investment Solutions’ holdings in Vertex Pharmaceuticals were worth $49,331,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Brighton Jones LLC boosted its stake in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares in the last quarter. Ritholtz Wealth Management raised its holdings in shares of Vertex Pharmaceuticals by 5.9% in the second quarter. Ritholtz Wealth Management now owns 3,662 shares of the pharmaceutical company’s stock valued at $1,630,000 after buying an additional 203 shares during the last quarter. Mutual Advisors LLC lifted its position in Vertex Pharmaceuticals by 6.2% during the 2nd quarter. Mutual Advisors LLC now owns 3,275 shares of the pharmaceutical company’s stock worth $1,538,000 after buying an additional 191 shares in the last quarter. Nordea Investment Management AB grew its holdings in Vertex Pharmaceuticals by 4.5% during the 2nd quarter. Nordea Investment Management AB now owns 24,512 shares of the pharmaceutical company’s stock worth $10,889,000 after acquiring an additional 1,057 shares during the last quarter. Finally, Angeles Wealth Management LLC increased its position in Vertex Pharmaceuticals by 2.3% in the 2nd quarter. Angeles Wealth Management LLC now owns 1,284 shares of the pharmaceutical company’s stock valued at $572,000 after acquiring an additional 29 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $491.47 on Friday. The firm’s fifty day moving average is $459.98 and its two-hundred day moving average is $427.48. The firm has a market cap of $124.70 billion, a PE ratio of 32.06 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.90%. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.98 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VRTX. Morgan Stanley reiterated an “overweight” rating and set a $570.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday. Barclays raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $414.00 to $606.00 in a report on Tuesday, January 27th. Evercore lifted their target price on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Oppenheimer raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price target on the stock in a research note on Friday. Finally, Scotiabank lifted their price objective on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research report on Friday. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $537.05.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Insiders Place Their Bets

In related news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company’s stock, valued at approximately $17,202,600. This represents a 27.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan Biller sold 1,925 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total transaction of $886,327.75. Following the completion of the transaction, the executive vice president directly owned 20,819 shares in the company, valued at approximately $9,585,692.17. The trade was a 8.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 99,352 shares of company stock worth $45,037,314 in the last three months. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.